RU2018114447A - Введение дейтерированных усилителей cftr - Google Patents
Введение дейтерированных усилителей cftr Download PDFInfo
- Publication number
- RU2018114447A RU2018114447A RU2018114447A RU2018114447A RU2018114447A RU 2018114447 A RU2018114447 A RU 2018114447A RU 2018114447 A RU2018114447 A RU 2018114447A RU 2018114447 A RU2018114447 A RU 2018114447A RU 2018114447 A RU2018114447 A RU 2018114447A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- compound
- paragraphs
- pharmaceutically acceptable
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (18)
1. Способ лечения состояния, которое опосредовано CFTR, у пациента, включающий введение пациенту соединения, представленного следующей структурной формулой
или его фармацевтически приемлемой соли
в количестве от 50 мг до 200 мг, один раз в сутки.
2. Способ по п. 1, где состоянием является муковисцидоз.
3. Способ по любому из пп. 1-2, включающий введение пациенту 100 мг Соединения (I) или его фармацевтически приемлемой соли в сутки.
4. Способ по любому из пп. 1-3, где соединение вводят перорально.
5. Способ по п. 4, где соединение вводят в составе фармацевтической композиции, которая является таблеткой.
6. Способ по п. 4, где соединение вводят в составе фармацевтической композиции, которая является гранулами.
7. Способ по любому из пп. 1-6, где любой атом, не обозначенный как дейтерий в любом из вариантов осуществления изобретения, указанных выше, присутствует в его натуральной изотопной обогащенности.
8. Фармацевтическая композиция, включающая фармацевтически приемлемый носитель или разбавитель и от 50 мг до 200 мг соединения представленного следующей структурной формулой
или его фармацевтически приемлемой соли.
9. Фармацевтическая композиция по п. 8, включающая 100 мг соединения (I).
10. Фармацевтическая композиция по п. 8 или 9, где фармацевтическая композиция подходит для перорального введения.
11. Фармацевтическая композиция по п. 8 или 9, где композицией является таблетка.
12. Фармацевтическая композиция по п. 8 или 9, где композицией является гранула.
13. Фармацевтическая композиция по любому из пп. 8-12, где композицию вводят один раз в сутки.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562221531P | 2015-09-21 | 2015-09-21 | |
| US62/221,531 | 2015-09-21 | ||
| US201562238511P | 2015-10-07 | 2015-10-07 | |
| US62/238,511 | 2015-10-07 | ||
| US201662348855P | 2016-06-10 | 2016-06-10 | |
| US62/348,855 | 2016-06-10 | ||
| PCT/US2016/052922 WO2017053455A1 (en) | 2015-09-21 | 2016-09-21 | Administration of deuterated cftr potentiators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018114447A true RU2018114447A (ru) | 2019-10-23 |
| RU2018114447A3 RU2018114447A3 (ru) | 2020-02-21 |
| RU2761344C2 RU2761344C2 (ru) | 2021-12-07 |
Family
ID=58387264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018114447A RU2761344C2 (ru) | 2015-09-21 | 2016-09-21 | Введение дейтерированных усилителей cftr |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20180353500A1 (ru) |
| EP (2) | EP4292588A3 (ru) |
| JP (2) | JP6849686B2 (ru) |
| KR (1) | KR20180058745A (ru) |
| CN (1) | CN108367002A (ru) |
| AU (2) | AU2016326441B2 (ru) |
| BR (1) | BR112018005454A2 (ru) |
| CA (1) | CA2998911C (ru) |
| HK (1) | HK1258472A1 (ru) |
| IL (2) | IL257993A (ru) |
| MA (1) | MA42950A (ru) |
| MX (1) | MX2018003331A (ru) |
| RU (1) | RU2761344C2 (ru) |
| SG (1) | SG10201913588YA (ru) |
| UA (1) | UA124619C2 (ru) |
| WO (1) | WO2017053455A1 (ru) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| TWI735416B (zh) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| US10196384B2 (en) | 2015-03-31 | 2019-02-05 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR modulators |
| CA2999529A1 (en) | 2015-09-25 | 2017-03-30 | Vertex Pharmaceuticals (Europe) Limited | Deuterated cftr potentiators |
| US10738030B2 (en) | 2016-03-31 | 2020-08-11 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| SG10201913595YA (en) | 2016-09-30 | 2020-02-27 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| WO2018107100A1 (en) | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| CA3066084A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US20200171015A1 (en) * | 2017-07-17 | 2020-06-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| ES2912657T3 (es) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| WO2019109021A1 (en) | 2017-12-01 | 2019-06-06 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| WO2019113476A2 (en) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| US11066417B2 (en) | 2018-02-15 | 2021-07-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| US20220047564A1 (en) | 2018-11-14 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| UY38630A (es) | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| FR3096890B1 (fr) | 2019-06-07 | 2021-05-14 | H4 Orphan Pharma | Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique. |
| TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| BR112022002606A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Moduladores do regulador de condutância transmembrana da fibrose cística |
| CA3150162A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| FR3109524B1 (fr) | 2020-04-22 | 2022-04-08 | H4 Orphan Pharma | Utilisation d’un ligand multifonctionnel pour traiter l’œil sec et les dysfonctionnements des glandes de Meibomius et des glandes lacrymales. |
| FR3111071B1 (fr) | 2020-06-04 | 2023-01-13 | H4 Orphan Pharma | Utilisation de ligands multifonctionnels pour traiter les syndromes de détresse respiratoire et le choc cytokinique liés aux infections virales à coronavirus. |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| CA3188787A1 (en) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| WO2022076628A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20240018161A1 (en) | 2020-10-07 | 2024-01-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20230104618A (ko) | 2020-10-07 | 2023-07-10 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막관통 전도도 조절자의 조절제 |
| WO2022076626A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230382924A1 (en) | 2020-10-07 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076627A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076618A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225750A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CR20230198A (es) | 2020-10-07 | 2023-07-03 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| MX2023006770A (es) | 2020-12-10 | 2023-08-14 | Vertex Pharma | Metodos de tratamiento para fibrosis quistica. |
| WO2023150237A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2023196429A1 (en) | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| HU229938B1 (en) | 2001-05-03 | 2015-01-28 | Hoffmann La Roche | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| US20060094744A1 (en) | 2004-09-29 | 2006-05-04 | Maryanoff Cynthia A | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| PL3219705T3 (pl) | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu |
| US20110288122A1 (en) * | 2010-05-20 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | Pharmaceutical Compositions and Administrations Thereof |
| ME02749B (me) * | 2011-05-18 | 2018-01-20 | Concert Pharmaceuticals Inc | Deuterisani derivati ivakaftora |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
| WO2014078842A1 (en) * | 2012-11-19 | 2014-05-22 | Concert Pharmaceuticals, Inc. | Deuterated cftr potentiators |
| CN109364075B (zh) * | 2012-11-21 | 2021-10-29 | 顶点制药（欧洲）有限公司 | 氘化cftr增效剂 |
| US20140221424A1 (en) * | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
-
2016
- 2016-09-21 JP JP2018534496A patent/JP6849686B2/ja active Active
- 2016-09-21 AU AU2016326441A patent/AU2016326441B2/en active Active
- 2016-09-21 EP EP23191452.4A patent/EP4292588A3/en active Pending
- 2016-09-21 US US15/761,532 patent/US20180353500A1/en not_active Abandoned
- 2016-09-21 KR KR1020187010964A patent/KR20180058745A/ko not_active Application Discontinuation
- 2016-09-21 WO PCT/US2016/052922 patent/WO2017053455A1/en active Application Filing
- 2016-09-21 BR BR112018005454A patent/BR112018005454A2/pt not_active Application Discontinuation
- 2016-09-21 EP EP16849524.0A patent/EP3352757B1/en active Active
- 2016-09-21 RU RU2018114447A patent/RU2761344C2/ru active
- 2016-09-21 MA MA042950A patent/MA42950A/fr unknown
- 2016-09-21 CA CA2998911A patent/CA2998911C/en active Active
- 2016-09-21 CN CN201680067707.1A patent/CN108367002A/zh active Pending
- 2016-09-21 UA UAA201804280A patent/UA124619C2/uk unknown
- 2016-09-21 SG SG10201913588YA patent/SG10201913588YA/en unknown
- 2016-09-21 MX MX2018003331A patent/MX2018003331A/es unknown
-
2018
- 2018-03-08 IL IL257993A patent/IL257993A/en unknown
-
2019
- 2019-01-17 HK HK19100788.5A patent/HK1258472A1/zh unknown
-
2020
- 2020-05-14 US US15/931,944 patent/US20200375973A1/en active Pending
-
2021
- 2021-03-04 JP JP2021034591A patent/JP7196217B2/ja active Active
-
2022
- 2022-02-21 AU AU2022201135A patent/AU2022201135B2/en active Active
- 2022-03-20 IL IL291517A patent/IL291517A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180353500A1 (en) | 2018-12-13 |
| WO2017053455A1 (en) | 2017-03-30 |
| MA42950A (fr) | 2018-08-01 |
| MX2018003331A (es) | 2018-08-16 |
| EP4292588A2 (en) | 2023-12-20 |
| IL257993A (en) | 2018-05-31 |
| EP3352757C0 (en) | 2023-08-16 |
| JP7196217B2 (ja) | 2022-12-26 |
| JP2018534348A (ja) | 2018-11-22 |
| HK1258472A1 (zh) | 2019-11-15 |
| CA2998911A1 (en) | 2017-03-30 |
| AU2022201135B2 (en) | 2024-03-28 |
| UA124619C2 (uk) | 2021-10-20 |
| EP4292588A3 (en) | 2024-02-28 |
| AU2016326441A1 (en) | 2018-04-19 |
| RU2761344C2 (ru) | 2021-12-07 |
| JP2021091723A (ja) | 2021-06-17 |
| CA2998911C (en) | 2023-05-23 |
| JP6849686B2 (ja) | 2021-03-24 |
| CN108367002A (zh) | 2018-08-03 |
| EP3352757A4 (en) | 2018-08-01 |
| BR112018005454A2 (pt) | 2018-10-09 |
| RU2018114447A3 (ru) | 2020-02-21 |
| KR20180058745A (ko) | 2018-06-01 |
| EP3352757B1 (en) | 2023-08-16 |
| IL291517A (en) | 2022-05-01 |
| SG10201913588YA (en) | 2020-02-27 |
| US20200375973A1 (en) | 2020-12-03 |
| EP3352757A1 (en) | 2018-08-01 |
| AU2022201135A1 (en) | 2022-03-17 |
| AU2016326441B2 (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| JP2018534348A5 (ru) | ||
| EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
| JP2013505205A5 (ru) | ||
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| JP2012193216A5 (ru) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| EA202090573A1 (ru) | Составы нирапариба | |
| CY1122626T1 (el) | Κορτικοστεροειδες που περιεχει τις συνθεσεις των δισκιων που διασπωνται απο το στομα για την ηωσινοφιλικη οισοφαγιτιδα | |
| JP2016511753A5 (ru) | ||
| JP2015510916A5 (ru) | ||
| JP2016510326A5 (ru) | ||
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| RU2016103764A (ru) | Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан | |
| MX2017015192A (es) | Derivado de bisamida de acido dicarboxilico como agente que estimula regeneracion de tejidos y recuperacion de funcion tisular disminuida. | |
| EA201590474A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ | |
| EA201792237A1 (ru) | Фармацевтические составы | |
| MX2017015202A (es) | Formulaciones liquidas de celecoxib para administracion oral. | |
| MX370184B (es) | Composición farmacéutica que comprende fingolimod. | |
| MX2018003890A (es) | Composiciones farmaceuticas que contienen un relajante muscular y un antiinflamatorio no esteroideo (aine). | |
| DK2091520T3 (da) | Oral doseringsform omfattende trisubstituerede glycerol-forbindelser |